Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patients | Zendy

Murat Türk | Zendy; İnsu Yılmaz | Zendy; Sakine Nazik Bahçecioğlu | Zendy

Open Access

Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patients

Author(s) -

Murat Türk,

İnsu Yılmaz,

Sakine Nazik Bahçecioğlu

Publication year - 2017

Publication title -

allergology international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.49

H-Index - 58

eISSN - 1440-1592

pISSN - 1323-8930

DOI - 10.1016/j.alit.2017.05.003

Subject(s) - omalizumab , discontinuation , medicine , concomitant , refractory (planetary science) , adverse effect , retrospective cohort study , immunoglobulin e , immunology , antibody , physics , astrobiology

Previous data have shown the high efficacy of omalizumab in chronic spontaneous urticaria (CSU). However, factors that may be effective on the response to therapy, relapse rates after drug discontinuation, and efficacy of retreatment remain unclear. This study aimed to determine the efficacy of omalizumab in CSU refractory to conventional therapy, to identify possible factors affecting treatment response and relapse, and also to evaluate the efficacy of retreatment on relapsed disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research